Logo

FBLG

FibroBiologics, Inc. Common Stock

FBLG

FibroBiologics, Inc. Common Stock • NASDAQ
$0.27 ▲ 0.70% (+0.00)
Market Cap $11.49 M
52w High $2.79
52w Low $0.24
Dividend Yield 0%
P/E -0.57
Volume 707.53K
Outstanding Shares 41.92M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $4.807M ▲ $-5.778M ▼ 0% $-0.13 ▼ $-5.547M ▼
Q2-2025 $0 $4.49M ▼ $-4.658M ▲ 0% $-0.12 ▲ $-4.452M ▲
Q1-2025 $0 $4.531M ▲ $-4.966M ▼ 0% $-0.14 ▼ $-4.805M ▼
Q4-2024 $0 $3.712M ▲ $-3.099M ▼ 0% $-0.089 ▼ $-2.94M ▼
Q3-2024 $0 $3.352M $-500K 0% $-0.01 $-352K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $4.867M ▼ $8.744M ▼ $8.619M ▼ $125K ▼
Q2-2025 $8.845M ▲ $13.907M ▲ $13.047M ▲ $860K ▼
Q1-2025 $8.667M ▼ $11.426M ▼ $9.076M ▼ $2.35M ▼
Q4-2024 $13.985M ▲ $16.445M ▲ $13.71M ▲ $2.735M ▼
Q3-2024 $7.827M $10.469M $7.732M $2.737M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-5.778M ▼ $-3.972M ▲ $-6K ▲ $0 ▼ $-3.978M ▼ $-3.978M ▲
Q2-2025 $-4.658M ▲ $-3.984M ▲ $-213K ▼ $4.375M ▲ $178K ▲ $-4.197M ▲
Q1-2025 $-4.966M ▼ $-5.275M ▼ $-43K ▲ $0 ▼ $-5.318M ▼ $-5.318M ▼
Q4-2024 $-3.099M ▼ $-3.073M ▼ $-99K ▼ $9.33M ▲ $6.158M ▲ $-3.172M ▼
Q3-2024 $-500K $-2.606M $-11K $4.471M $1.854M $-2.617M

Five-Year Company Overview

Income Statement

Income Statement FibroBiologics is still a pure research-stage company with no product revenue yet. Its costs are mainly research and overhead, which has led to small but consistent losses over the past few years. The pattern is what you’d expect from an early biotech: money going out to fund science and trials, with no commercial income coming in yet. The improvement in recent-year losses is modest and does not change the basic picture that the business is still firmly pre‑revenue and dependent on outside funding.

Balance Sheet

Balance Sheet The balance sheet is very light, reflecting a young company that has only recently come public. Assets are small and largely made up of cash, with only a thin layer of equity and a bit of debt in the mix. This means there isn’t a large asset cushion to fall back on. The company’s future financial health will depend less on existing resources and more on its ability to keep raising capital as it advances its pipeline.

Cash Flow

Cash Flow Cash flows show a straightforward story: cash is being used to fund operations and research, with no meaningful investment in physical assets and no incoming cash from products. Free cash flow is negative, which is normal for a clinical‑stage biotech but underscores that the company will likely need periodic external financing to sustain its programs and trials. The main risk is how long current cash can support operations before additional capital is required.

Competitive Edge

Competitive Edge FibroBiologics’ main strengths are its focus on fibroblast-based therapies, which is a less crowded niche than some other cell therapy areas, and a broad patent portfolio that helps protect its science. It also benefits from first‑mover status in this specific approach and partnerships for manufacturing. However, it operates in a highly competitive field with many larger, better‑funded biotech and pharma companies. Its competitive position will ultimately be judged on clinical results, safety, and the ability to scale manufacturing and secure partners, all of which are still in early stages.

Innovation and R&D

Innovation and R&D Innovation is the core of FibroBiologics. The company is building a platform around fibroblast cells that can potentially be used across multiple diseases, from wound healing and multiple sclerosis to disc disease and psoriasis, with additional early work in cancer and aging-related immune decline. The ability to derive several product candidates from a common cell bank could offer efficiency and scale advantages. That said, most programs are at early or mid clinical and preclinical stages, so scientific promise still needs to translate into clear clinical success and regulatory approvals, which is inherently uncertain.

Summary

FibroBiologics is a very early-stage, research-driven biotech with a novel angle on regenerative medicine but no commercial products yet. Financially, it has a thin balance sheet, ongoing losses, and negative cash flow, all typical for a company at this point in the biotech lifecycle and implying continued reliance on external funding. Strategically, it leans on a sizable patent estate, a differentiated fibroblast platform, and a diversified pipeline, offering multiple shots on goal but also spreading execution risk. The key drivers of its future outlook will be clinical trial results, regulatory progress, and its ability to secure capital and partnerships as programs advance. As with most clinical-stage biotechs, the opportunity is closely tied to high scientific and development risk.

NEWS

November 26, 2025 · 8:30 AM UTC

FibroBiologics Announces Payoff of Outstanding Debt

Read more

November 25, 2025 · 4:05 PM UTC

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Read more

November 24, 2025 · 9:00 AM UTC

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Read more

November 20, 2025 · 8:00 AM UTC

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Read more

November 19, 2025 · 7:03 PM UTC

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Read more